利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

513 条记录 (耗时 0.038 秒)

    METHOD FOR PRODUCTION OF HEPARIN AND HEPARAN SULFATE
    2.
    发明公开
    METHOD FOR PRODUCTION OF HEPARIN AND HEPARAN SULFATE 审中-公开
    生产肝素和硫酸肝素的方法

    公开(公告)号：EP3289086A1

    公开(公告)日：2018-03-07

    申请号：EP16785687.1

    申请日：2016-04-28

    申请人： NewSouth Innovations Pty Limited

    发明人： WHITELOCK, John M. ,  LORD, Megan S.

    IPC分类号： C12N15/12 ,  C12N5/10 ,  C12N5/22 ,  A61K38/17 ,  A61K38/36 ,  C07K14/435

    CPC分类号： C08B37/0075 ,  A61K31/727 ,  A61K38/00 ,  C07K14/4725 ,  C07K2319/02 ,  C07K2319/20 ,  C08B37/0003 ,  C12N2510/00 ,  C12N2510/02 ,  C12P19/26 ,  C12P21/005

    摘要： This present disclosure relates to a method of producing a proteoglycan having anticoagulant activity, comprising of and providing a cell transfected with a recombinant nucleic acid encoding a core protein having one or more glycosaminoglycan attachment sites; and incubating the cell under conditions to promote the production of a proteoglycan comprising the core protein linked to heparin and/or HS and optionally other glycosaminoglycan chains, and to heparin or heparan sulphate isolated from such proteoglycans that have significant anti-coagulant activity. The invention also relates to a recombinant proteoglycan comprising a core protein and heparin and/or heparan sulfate, to a cell capable of producing a proteoglycan comprising the core protein and heparin and/or heparan sulfate, and to a method of treating or preventing blood coagulation, or a condition associated with blood coagulation, using the recombinant proteoglycan comprising a core protein and heparin and/or heparan sulfate and/or the heparin and/or heparan sulfate isolated from such proteoglycans.

    INDIRECT HOMOGENEOUS MOBILITY SHIFT ASSAYS FOR THE DETECTION OF BIOLOGICS IN PATIENT SAMPLES
    6.
    发明公开
    INDIRECT HOMOGENEOUS MOBILITY SHIFT ASSAYS FOR THE DETECTION OF BIOLOGICS IN PATIENT SAMPLES 审中-公开
    用于检测患者样本中生物制剂的间接齐性移动换档测定

    公开(公告)号：EP3227683A2

    公开(公告)日：2017-10-11

    申请号：EP15816881.5

    申请日：2015-12-04

    申请人： Nestec S.A.

    发明人： SALBATO, Jared ,  WESTIN, Stefan ,  CHI-KWAN LING, Nicholas ,  JAIN, Anjali ,  SINGH, Sharat

    IPC分类号： G01N33/537 ,  G01N33/58 ,  G01N33/94

    CPC分类号： G01N33/94 ,  C07K14/5434 ,  C07K14/70546 ,  C07K2319/20 ,  C07K2319/50 ,  G01N33/537 ,  G01N33/564 ,  G01N33/58 ,  G01N33/6854 ,  G01N2333/54 ,  G01N2333/5434 ,  G01N2333/70546 ,  G01N2800/065 ,  G01N2800/52

    摘要： The present invention provides a sensitive and specific indirect homogeneous mobility shift assay using size exclusion chromatography to measure biologics such as vedolizumab and ustekinumab in a patient sample. The assays of the present invention are particularly advantageous for detecting the presence or level of biologics that target complex or large antigens including cell surface proteins, transmembrane proteins, heavily glycosylated proteins, and multimeric proteins, as well as antigens that cannot be purified, impure antigens, and partially or substantially purified antigens. The present invention also provides isolated soluble α4β7 integrin heterodimers and isolated soluble IL-12p40 monomers that are suitable for use in the indirect assays described herein.

    摘要翻译： 本发明提供了使用尺寸排阻色谱法来测量患者样品中的生物制剂如维多珠单抗和ustekinumab的敏感且特异性的间接均质迁移率变动分析。 本发明的测定法对于检测靶向包括细胞表面蛋白质，跨膜蛋白质，重度糖基化蛋白质和多聚体蛋白质的复合或大抗原的生物制剂的存在或水平是特别有利的，以及不能纯化的抗原，不纯的抗原 和部分或基本上纯化的抗原。 本发明还提供了适用于本文所述的间接测定的分离的可溶性α4β7整联蛋白异二聚体和分离的可溶性IL-12p40单体。

    ELICITOR PEPTIDES HAVING DISRUPTED HYPERSENSITIVE RESPONSE BOX AND USE THEREOF
    8.
    发明公开
    ELICITOR PEPTIDES HAVING DISRUPTED HYPERSENSITIVE RESPONSE BOX AND USE THEREOF 审中-公开
    具有破坏性过敏反应盒的ELICITOR肽及其用途

    公开(公告)号：EP3201223A1

    公开(公告)日：2017-08-09

    申请号：EP15845670.7

    申请日：2015-10-01

    申请人： Plant Health Care, Inc.

    发明人： WEI, Zhongmin ,  ZORNETZER, Gregory A.

    IPC分类号： C07K14/415 ,  C07K4/10

    CPC分类号： A01N37/46 ,  A01N63/02 ,  C07K7/08 ,  C07K14/001 ,  C07K14/195 ,  C07K14/21 ,  C07K14/27 ,  C07K2319/00 ,  C07K2319/20 ,  C12N15/8279 ,  C12N15/8283 ,  A01N25/02

    摘要： Disclosed are peptides that induce an active plant response, but not a hypersensitive response, when applied to plant tissue. These peptides also preferably exhibit improved solubility, stability, resistance to chemical degradation, or a combination of these properties. Use of these peptides or fusion polypeptides, or DNA constructs encoding the same, for modulating plant biochemical signaling, imparting disease resistance to plants, enhancing plant growth, imparting tolerance to biotic stress, imparting tolerance and resistance to abiotic stress, imparting desiccation resistance to cuttings removed from ornamental plants, imparting post-harvest disease or post-harvest desiccation resistance to a fruit or vegetable, or enhancing the longevity of fruit or vegetable ripeness are also disclosed.

    摘要翻译： 公开了当施用于植物组织时诱导活性植物响应而不是超敏反应的肽。 这些肽还优选表现出改善的溶解性，稳定性，对化学降解的抗性或这些性质的组合。 这些肽或融合多肽或编码其的DNA构建体用于调节植物生物化学信号传导，赋予植物抗病性，增强植物生长，赋予对生物胁迫的耐受性，赋予对非生物胁迫的耐受性和抗性，赋予插穗抗干旱性 从观赏植物中除去，赋予果实或蔬菜收获后疾病或收获后干燥抗性，或增加水果或蔬菜成熟的寿命。

    ANTIBODIES SPECIFIC FOR IL-17A FUSED TO HYALURONAN BINDING PEPTIDE TAGS
    10.
    发明公开
    ANTIBODIES SPECIFIC FOR IL-17A FUSED TO HYALURONAN BINDING PEPTIDE TAGS 审中-公开
    与透明质酸结合肽标签融合的IL-17A特异性抗体

    公开(公告)号：EP3161001A2

    公开(公告)日：2017-05-03

    申请号：EP15741338.6

    申请日：2015-06-23

    申请人： Novartis AG

    发明人： DI PADOVA, Franco E. ,  GHOSH, Joy ,  HUBER, Thomas ,  RONDEAU, Jean-Michel Rene

    IPC分类号： C07K16/24 ,  A61K39/395 ,  C07K14/47 ,  A61K39/00

    CPC分类号： C07K16/244 ,  A61K39/3955 ,  A61K47/48546 ,  A61K2039/505 ,  C07K14/47 ,  C07K2317/21 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2317/94 ,  C07K2319/20 ,  C07K2319/30 ,  C07K2319/33 ,  C07K2319/35 ,  C07K2319/70

    摘要： The present disclosure relates to antibodies and proteins comprising an antigen-binding portion thereof that specifically bind to the pro-inflammatory cytokine IL-17A and a peptide tag that binds hyaluronan (HA). The disclosure more specifically relates to specific antibodies and proteins that are IL-17A antagonists (inhibit the activities of IL-17A and IL-17AF) and are capable of inhibiting IL-17A induced cytokine production in in vitro assays, and having an inhibitory effect in an antigen-induced arthritis model in vivo. The disclosure further relates to compositions and methods of use for said antibodies and proteins to treat pathological disorders that can be treated by inhibiting IL-17A or IL17AF mediated activity, such as rheumatoid arthritis, psoriasis, systemic lupus erythematosus (SLE), lupus nephritis, chronic obstructive pulmonary disease, asthma or cystic fibrosis or other autoimmune and inflammatory disorders.

    摘要翻译： 本公开涉及抗体和蛋白质，其包含特异性结合促炎细胞因子IL-17A的抗原结合部分和结合透明质酸（HA）的肽标签。 本公开更具体地涉及作为IL-17A拮抗剂（抑制IL-17A和IL-17AF的活性）并且能够在体外测定中抑制IL-17A诱导的细胞因子产生并且具有抑制作用的特异性抗体和蛋白质 在体内抗原诱导的关节炎模型中。 本公开还涉及用于所述抗体和蛋白质以治疗可通过抑制IL-17A或IL17AF介导的活性（例如类风湿性关节炎，牛皮癣，系统性红斑狼疮（SLE），狼疮肾炎等）治疗的病理学病症的组合物和方法。 慢性阻塞性肺病，哮喘或囊性纤维化或其他自身免疫性和炎症性疾病。